A novel urethral sparing technique for high-dose-rate prostate brachytherapy after transurethral resection of the prostate

被引:0
|
作者
Kunogi, Hiroaki [1 ,2 ]
Cunha, Jason Adam M. [1 ]
Chang, Albert J. [1 ]
Gadzinski, Adam J. [3 ]
Shinohara, Katsuto [3 ]
Hsu, I-Chow [1 ]
机构
[1] Univ Calif San Francisco, Dept Radiat Oncol, 1600 Divisadero St,H1031, San Francisco, CA 94143 USA
[2] Juntendo Univ, Dept Radiat Oncol, Bunkyo Ku, Tokyo, Japan
[3] Univ Calif San Francisco, Dept Urol, San Francisco, CA USA
关键词
Brachytherapy; HDR; Prostate; TURP; Urinary catheter; CANCER; RADIOTHERAPY; TOXICITY;
D O I
10.1016/j.brachy.2017.07.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE: The purpose of this study was to assess retrospectively the variability of the urethral dose optimized using a Foley catheter versus urethral contrast injected using a new modified triple-lumen catheter, in CT-based high-dose-rate (HDR) prostate brachytherapy of posttransurethral resection of prostate (TURP) patients. METHODS AND MATERIALS: At our institution, there were six post-TURP patients with prostate carcinoma between July 2014 and April 2016 who underwent transperineal interstitial HDR brachytherapy (16 needles). A custom modified triple-lumen catheter was placed to inject contrast into the TURP defect. Three-dimensional optimal plans using inverse planning simulated annealing algorithm was generated according to radiation therapy oncology group dose requirements. Alternative plans were retroactively generated for comparison using standard technique based on a Foley catheter as a urethral constraint volume for each patient with the same weighting factors. We compared the dosimetry parameters in each planning using Wilcoxon's ranked sum nonparametric test. RESULTS: The median followup of all patients was 17.5 months. No significant genitourinary or gastrointestinal toxicity was noted using this technique. In the dosimetric analysis, the prostate V-100 values and TURP urethral V100 were significantly different between plans with and without the contrast (V100 [mean]: 92.4 [%] vs. 94.4 [%], p = 0.046; TURP UV100 [mean]: 1.4 cc vs. 2.2 cc, p = 0.028). There were no statistical differences in the mean values of planning target volume V-150%, V(20)0%, and D-90, and each bladder V-75 and rectum (V75). CONCLUSIONS: Post-TURP HDR brachytherapy with urethral contrast showed significantly more volume effect of the TURP defect than that with a Foley catheter alone. Better visualization of the TURP defect should lead to more accurate urethral sparing administration of HDR brachytherapy which is necessary to prevent urethral complication. (C) 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1113 / 1118
页数:6
相关论文
共 50 条
  • [31] Urinary incontinence after high-dose-rate brachytherapy boost treatment for prostate cancer
    Kragelj, Borut
    Zaletel-Kragelj, Lijana
    BRACHYTHERAPY, 2016, 15 (04) : 442 - 449
  • [32] Salvage High-Dose-Rate Brachytherapy for Recurrent Prostate Cancer After Definitive Radiation
    Wu, Susan Y.
    Wong, Anthony C.
    Shinohara, Katsuto
    Roach, Mack, III
    Cunha, Adam M.
    Valdes, Gilmer
    Hsu, I-Chow
    PRACTICAL RADIATION ONCOLOGY, 2021, 11 (06) : 515 - 526
  • [33] Comparison of dose and catheter optimization algorithms in prostate high-dose-rate brachytherapy
    Poulin, Eric
    Varfalvy, Nicolas
    Aubin, Sylviane
    Beaulieu, Luc
    BRACHYTHERAPY, 2016, 15 (01) : 102 - 111
  • [34] Monotherapeutic high-dose-rate brachytherapy for prostate cancer: A dose reduction trial
    Yoshioka, Yasuo
    Konishi, Koji
    Suzuki, Osamu
    Nakai, Yasutomo
    Isohashi, Fumiaki
    Seo, Yuji
    Otani, Yuki
    Koizumi, Masahiko
    Yoshida, Ken
    Yamazaki, Hideya
    Nonomura, Norio
    Ogawa, Kazuhiko
    RADIOTHERAPY AND ONCOLOGY, 2014, 110 (01) : 114 - 119
  • [35] Parameterised rectal dose and associations with latetoxicity in high-dose-rate prostate brachytherapy
    Hamlett, L.
    Wood, D. A.
    Aitkenhead, A.
    Hodgson, C.
    Wylie, J.
    Choudhury, A.
    Logue, J.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S88 - S88
  • [36] Urethral metastasis after transurethral resection of a malignant prostate
    Madaan, S
    Abel, PD
    BJU INTERNATIONAL, 2001, 88 (03) : 308 - 308
  • [37] High-Dose-Rate Interstitial Brachytherapy as Monotherapy in Prostate Cancer Patients
    Kazberuk, D.
    Filipowski, T.
    Szmigiel-Trzcinska, A.
    Niksa, M.
    Hempel, D.
    Pancewicz-Janczuk, B.
    Nowik, W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S448 - S448
  • [38] Validation of MRI to TRUS registration for high-dose-rate prostate brachytherapy
    Poulin, Eric
    Boudam, Karim
    Pinter, Csaba
    Kadoury, Samuel
    Lasso, Andras
    Fichtinger, Gabor
    Menard, Cynthia
    BRACHYTHERAPY, 2018, 17 (02) : 283 - 290
  • [39] Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer
    Maenhout, Metha
    van Vulpen, Marco
    Moerland, Marinus
    Peters, Max
    Meijer, Richard
    van den Bosch, Maurice
    Nguyen, Paul
    Frank, Steven
    van Zyp, Jochem van der Voort
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2017, 9 (02) : 161 - 166
  • [40] Why stop at using high-dose-rate brachytherapy as a boost for the prostate?
    Beitler, J
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) : 4003 - 4004